TY - JOUR
T1 - Plasmablastic Lymphoma
T2 - Past, Present, and Future
AU - Kaur, Supreet
AU - Kollimuttathuillam, Sudarsan
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/9
Y1 - 2023/9
N2 - Plasmablastic Lymphoma is a rare large B-cell lymphoma with unique immunohistochemical and morphological features. It was most commonly associated with HIV infection; however, it's now seen in other immunosuppressed states like autoimmune conditions, post-transplant settings, and even in elderly immunocompetent individuals. Although rare, it is an aggressive lymphoma with unfavorable outcomes. The aim of this manuscript is to have an in-depth review of the current knowledge of epidemiology, pathophysiology, prognostic markers, and treatment approaches currently in use and in clinical trials for this challenging disease.
AB - Plasmablastic Lymphoma is a rare large B-cell lymphoma with unique immunohistochemical and morphological features. It was most commonly associated with HIV infection; however, it's now seen in other immunosuppressed states like autoimmune conditions, post-transplant settings, and even in elderly immunocompetent individuals. Although rare, it is an aggressive lymphoma with unfavorable outcomes. The aim of this manuscript is to have an in-depth review of the current knowledge of epidemiology, pathophysiology, prognostic markers, and treatment approaches currently in use and in clinical trials for this challenging disease.
KW - BCMA
KW - CART
KW - Daratumumab
KW - HIV
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85166942848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85166942848&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2023.05.014
DO - 10.1016/j.clml.2023.05.014
M3 - Review article
C2 - 37453866
AN - SCOPUS:85166942848
SN - 2152-2650
VL - 23
SP - e253-e259
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 9
ER -